RecruitingPhase 2NCT06056336

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Perioperative Immunoagent (Tislelizumab) Plus Chemotherapy for Locally Advanced Resectable Thoracic Oesophageal Squamous Cell Carcinoma Trail:A Prospective Single-arm,Phase II Study (PILOT Trail)

Sponsor

Guo Xufeng

Enrollment

73 participants

Start Date

Sep 7, 2023

Study Type

INTERVENTIONAL

Conditions

Esophageal Squamous Cell Carcinoma Adjuvant Therapy Neoadjuvant Chemoimmunotherapy

Summary

The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved survival outcomes.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy given both before and after surgery can improve outcomes for people with resectable squamous cell cancer of the esophagus (the food pipe) located in the chest. **You may be eligible if...** - You have been confirmed to have squamous cell carcinoma of the thoracic esophagus - Your cancer is staged as cT1b-3N1-3M0 or T3N0M0 (locally advanced but operable) and you have not had any prior treatment - You are between 18 and 75 years old with an ECOG score of 0–1 - Surgery to fully remove the tumor (R0 resection) is expected to be possible **You may NOT be eligible if...** - You have previously received chemotherapy, radiation, or immunotherapy for esophageal cancer - You have significant heart problems - You are pregnant or breastfeeding - You have active autoimmune disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTislelizumab

Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.